Scarica l'app Stockscreener
6.715
1.40%
-0.065
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.78
Aprire:
$6.66
Volume 24 ore:
287.40K
Relative Volume:
0.48
Capitalizzazione di mercato:
$405.87M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-3.5718
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
-4.36%
1M Prestazione:
-26.54%
6M Prestazione:
+63.05%
1 anno Prestazione:
+119.18%
Intervallo 1D:
$6.50
$6.805
Intervallo di 1 settimana:
$6.50
$7.19
Portata 52W:
$2.965
$13.60
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
6.71 | 405.87M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.67 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.43 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.62 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.99 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Franklin Resources Inc. Makes New Investment in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Sold by ExodusPoint Capital Management LP - The AM Reporter
Vanguard Group Inc. Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Raymond James Financial Inc. Invests $124,000 in Omeros Co. (NASDAQ:OMER) - Defense World
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Corebridge Financial Inc. Sells 2,100 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' New Leukemia Drug Team Ignites Hope For Cancer FightOmeros (NASDAQ:OMER) - Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee - GuruFocus
Omeros forms steering committee for leukemia treatment By Investing.com - Investing.com South Africa
Omeros announces oncology clinical steering committee to help guide proprietary Oncotox-AML clinical program - marketscreener.com
Omeros forms steering committee for leukemia treatment - Investing.com
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program - The Joplin Globe
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases - Yahoo Finance
Revolutionary T-CAT Platform Takes Aim at $135B Antibiotic Crisis with 99% Kill Rate - Stock Titan
It makes sense and dollars to buy Omeros Corporation (OMER) stock - Sete News
(OMER) Technical Data - news.stocktradersdaily.com
FY2025 EPS Estimates for Omeros Reduced by Cantor Fitzgerald - Defense World
Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com - The AM Reporter
Omeros (NASDAQ:OMER) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP - Defense World
Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC - Defense World
Omeros Corporation’s Earnings Call Highlights Progress and Challenges - TipRanks
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Exceeds Q4 EPS Expectations, Reports Cash Decline - GuruFocus
Omeros: Q4 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with Strategic Initiatives - GuruFocus
Omeros Corporation Reports 2024 Financial Results - TipRanks
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com Canada
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com Australia
OMEROS CORP SEC 10-K Report - TradingView
Omeros reports Q4 EPS (54c), consensus (71c) - TipRanks
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Omeros Earnings Preview: Key Metrics to Watch in Q4 and Full Year Report - Stock Titan
Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Bank of New York Mellon Corp Sells 4,919 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.77%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):